Skip to main content

Table 2 Analytical performance data for the simultaneous determination of BUD and AZL by the proposed HPLC and spectrophotometric methods

From: Insights of different analytical approaches for estimation of budesonide as COVID-19 replication inhibitor in its novel combinations: green assessment with AGREE and GAPI approaches

Drug

BUD

AZL

Parameter

HPLC method

First derivative

Ratio first derivative

HPLC method

Zero order method

BUD sum epimer B + A

BUD epimer B

BUD epimer A

265 nm

270 nm

290 nm

Range of linearity (μg mL−1)

0.4–40.0

6.0–20.0

6.0–20.0

0.05–40.0

1.0–35.0

Correlation coefficient (r)

0.9999

Slope (a)

13.31

13.31

13.31

17 × 10–4

38 × 10–4

47.48

26 × 10–3

Intercept (b)

− 0.36

− 0.07

− 0.29

18 × 10–4

− 19 × 10–4

0.89

34 × 10–3

% RSDa

0.72

0.75

0.68

0.81

0.85

0.84

0.76

% Errorb

0.25

0.27

0.24

0.29

0.3

0.30

0.24

S.D. of residuals (Sy/x)

0.844

0.429

0.415

19 × 10–5

45 × 10–5

0.23

26 × 10–4

S.D. of intercept (Sa)

0.457

0.233

0.225

22 × 10–5

4 × 10–5

0.111

136 × 10–5

S.D. of slope (Sb)

0.023

0.023

0.022

2 × 10–5

5 × 10–4

0.006

7 × 10–5

LOD (μg mL−1)c

0.113

0.058

0.056

0.43

0.43

0.008

0.17

LOQ (μg mL−1)d

0.343

0.175

0.170

1.29

1.32

0.023

0.52

  1. aPercentage relative standard deviation
  2. bPercentage relative error
  3. cLimit of detection
  4. dLimit of quantitation